Vontobel Holding Ltd. sold 18,760 shares of Biogen Inc, while
Swedbank AB increased its stake in the company, amid mixed reviews from evaluations. The
HSBC downgraded Biogen Inc but RBC Capital maintained a Buy rating on it. Biogen made major progress in its pipeline with their recent
QALSODY data and
advances in ALS treatment. The
Phase 3 Study of QALSODY has shown promising results that have generated renewed growth optimism. Biogen's shares have seen fluctuations and its
stock trades have been the centre of attention. Several companies have garnered a new interest in Biogen or increased their investment,
including Pacer Advisors Inc, Fluent Financial LLC and Wedge Capital Management. Biogen’s new data and partnerships are significantly altering the investment landscape for the company. Moreover, Biogen’s recently approved
Leqembi medicine is being viewed as a revolutionary advancement in early Alzheimer’s disease treatment. However,
a one-time $471M loss has raised some concerns regarding its rebounding profit narrative.
Biogen BIIB News Analytics from Tue, 15 Apr 2025 07:00:00 GMT to Sat, 27 Dec 2025 13:46:57 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor 3
